Program
Trazodone
Also written as “Trazodone HCl”, “Trazodone 20 mg” and “150 mg trazodone hydrochloride”.
Its studies are mostly in Depression · Diabetic Neuropathies · Depressive Disorder, Major · Sleep Wake Disorders, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Angelini Pharma | 50 open or running | phase 3since Mar 12, 2014 | Mar 12, 2014 | none ahead |
| Labopharm | 50 open or running | phase 3since Oct 17, 2008 | Oct 17, 2008 | none ahead |
| Lee's Pharmaceutical | 30 open or running | phase 3since Jan 13, 2012 | Jan 13, 2012 | none ahead |
| Targeted Medical Pharma | 10 open or running | phase 3since Nov 5, 2011 | Nov 5, 2011 | none ahead |
Also a collaborator on its studies: chiltern-international-inc, cross-research-s-a, eresearch-technology-inc and algorithme-pharma-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 17, 2008First study: phase 3 study in Depressive Disorder, MajorNew to LabopharmLabopharm · NCT00775203 · 412 enrolled · United States, Canada
- Feb 6, 2009Phase 1 study in HealthyLabopharm · NCT00839072 · 24 enrolled · Canada
- May 10, 20103 phase 1 studiesLabopharm · NCT01121926, NCT01121913, NCT01121900
- Nov 5, 2011Targeted Medical Pharma's first study: phase 3 study in Sleep Wake DisordersNew to Targeted Medical PharmaTargeted Medical Pharma · NCT01468038 · 111 enrolled · United States
- Jan 13, 2012Lee's Pharmaceutical's first study: phase 3 study in DepressionNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT01524497 · 382 enrolled · China
- Mar 12, 2014Angelini Pharma's first study: phase 3 study in Depressive Disorder, MajorNew to Angelini PharmaAngelini Pharma · NCT02086929 · 364 enrolled · Austria, Czech Republic, Italy and more
- May 24, 20162 phase 1 studies in DepressionLee's Pharmaceutical · NCT02785614, NCT02785601
- Jun 23, 2017Phase 2 study in Diabetic NeuropathiesAngelini Pharma · NCT03202979 · 142 enrolled · Czechia, Hungary, Poland
- Apr 24, 2018Phase 1 study in HealthyAngelini Pharma · NCT03516630 · 20 enrolled · Switzerland
- Nov 20, 2018Phase 2 study in Diabetic NeuropathiesAngelini Pharma · NCT03749642 · 240 enrolled · Czechia, France, Poland and more
- Dec 20, 2024Phase 1 study in Bioavailability Heathy VolunteersAngelini Pharma · NCT06773767 · 64 enrolled · Germany
TargetBeta
“Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06773767Bioavailability Heathy Volunteers · Germany | 1 | Completed | Angelini Pharma | Aug 7, 2024 | 64 |
| NCT03749642Diabetic Neuropathies · Czechia, France, Poland and more | 2 | Completed | Angelini Pharma | Jun 6, 2020 | 240 |
| NCT03516630Healthy · Switzerland | 1 | Completed | Angelini Pharma | May 1, 2017 | 20 |
| NCT03202979Diabetic Neuropathies · Czechia, Hungary, Poland | 2 | Completed | Angelini Pharma | Aug 9, 2018 | 142 |
| NCT02785614Depression · Hong Kong | 1 | Completed | Lee's Pharmaceutical | Nov 30, 2017 | 12 |
| NCT02785601Depression · Hong Kong | 1 | Completed | Lee's Pharmaceutical | Nov 30, 2017 | 15 |
| NCT02086929Depressive Disorder, Major · Austria, Czech Republic, Italy and more | 3 | Completed | Angelini Pharma | Apr 2014 | 364 |
| NCT01524497Depression · China | 3 | Completed | Lee's Pharmaceutical | Aug 2013 | 382 |
| NCT01468038Sleep Wake Disorders · United States | 3 | Completed | Targeted Medical Pharma | Oct 2008 | 111 |
| NCT01121926Healthy Subjects | 1 | Completed | Labopharm | Mar 2008 | 30 |
| NCT01121913Healthy | 1 | Completed | Labopharm | Apr 2005 | 24 |
| NCT01121900Healthy | 1 | Completed | Labopharm | Jul 2008 | 26 |
| NCT00839072Healthy · Canada | 1 | Completed | Labopharm | Feb 2009 | 24 |
| NCT00775203Depressive Disorder, Major · United States, Canada | 3 | Completed | Labopharm | Nov 2007 | 412 |
How it is read
Names in the registry
- “Trazodone HCl”, 10 entries
- “Trazodone”, 3 entries
- “Trazodone 20 mg”, 2 entries
- “150 mg trazodone hydrochloride”, 1 entry
- “300 mg trazodone hydrochloride”, 1 entry
Conditions, from the studies’ own filings
- Depression, 3 studies
- Diabetic Neuropathies, 2 studies
- Depressive Disorder, Major, 2 studies
- Sleep Wake Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.